서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

Login

S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 8 of 8

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2011-10	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Shaw, Alice T.; Yeap, Beow Y.; Solomon, Benjamin J.; Riely, Gregory J.; Gainor, Justin; Engelman, Jeffrey A.; Shapiro, Geoffrey I.; Costa, Daniel B.; Ou, Sai-Hong I.; Butaney, Mohit; Salgia, Ravi; Maki, Robert G.; Varella-Garcia, Marileila; Doebele, Robert C.; Bang, Yung-Jue; Kulig, Kimary; Selaru, Paulina; Tang, Yiyun; Wilner, Keith D.; Kwak, Eunice L.; Clark, Jeffrey W.; Iafrate, A. John; Camidge, D. Ross The Lancet Oncology, Vol.12 No.11, pp.1004-1012	DOI
2012-06	Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Non-Small-Cell Lung Cancer Kim, Su-Jung; Kim, Dong-Wan; Kim, Tae Min; Lee, Se-Hoon; Heo, Dae Seog; Bang, Yung-Jue Journal of Clinical Oncology, Vol.30 No.16, pp.E147-E150	DOI
2013-03	Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT Choi, Hongyoon; Paeng, Jin Chul; Kim, Dong-Wan; Lee, June Koo; Park, Chang Min; Kang, Keon Wook; Chung, June-Key; Lee, Dong Soo Lung Cancer, Vol.79 No.3, pp.242-247	DOI
2013-09	Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment Huang, Donghui; Kim, Dong-Wan; Kotsakis, Athanasios; Deng, Shibing; Lira, Paul; Ho, Steffan N.; Lee, Nathan V.; Vizcarra, Pamela; Cao, Joan Q.; Christensen, James G.; Kim, Tae Min; Sun, Jong-mu; Ahn, Jin Seok; Ahn, Myung-Ju; Park, Keunchil; Mao, Mao Genomics, Vol.102 No.3, pp.157-162	DOI
2014-11	Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer Shaw, Alice T.; Ou, Sai-Hong I.; Bang, Yung-Jue; Camidge, D. Ross; Solomon, Benjamin J.; Salgia, Ravi; Riely, Gregory J.; Varella-Garcia, Marileila; Shapiro, Geoffrey I.; Costa, Daniel B.; Doebele, Robert C.; Long Phi Le; Zheng, Zongli; Tan, Weiwei; Stephenson, Patricia; Shreeve, S. Martin; Tye, Lesley M.; Christensen, James G.; Wilner, Keith D.; Clark, Jeffrey W.; Iafrate, A. John New England Journal of Medicine, Vol.371 No.21, pp.1963-1971	DOI
2016-03	EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1 alpha and STAT3 Koh, Jaemoon; Jang, Ji-Young; Keam, Bhumsuk; Kim, Sehui; Kim, Moon-Young; Go, Heounjeong; Kim, Tae Min; Kim, Dong-Wan; Kim, Chul-Woo; Jeon, Yoon Kyung; Chung, Doo Hyun OncoImmunology, Vol.5 No.3, p. e1108514	DOI
2018-11	Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer Camidge, D. Ross; Kim, Hye Ryun; Ahn, Myung-Ju; Yang, James Chih-Hsin -H.; Han, Ji-Youn; Lee, Jong-Seok; Hochmair, Maximilian J.; Li, Jacky Yu-Chung; Chang, Gee-Chen; Lee, Ki Hyeong; Gridelli, Cesare; Delmonte, Angelo; Garcia Campelo, Rosario; Kim, Dong-Wan; Bearz, Alessandra; Griesinger, Ffrank; Morabito, Alessandro; Felip, Enriqueta; Califano, Raffaele; Ghosh, Sharmistha; Spira, Alexander; Gettinger, Scott N.; Tiseo, Marcello; Gupta, Neeraj; Haney, Jeff; Kerstein, David; Popat, Sanjay New England Journal of Medicine, Vol.379 No.21, pp.2027-2039	DOI
2023-12	Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial Yang, James Chih-Hsin; Liu, Geoffrey; Lu, Shun; He, Jianxing; Burotto, Mauricio; Ahn, Myung-Ju; Kim, Dong-Wan; Liu, XiaoQing; Zhao, Yanqiu; Vincent, Sylvie; Yin, Jiani; Ma, Xin; Lin, Huamao M.; Popat, Sanjay Journal of Thoracic Oncology, Vol.18 No.12, pp.1743-1755	DOI

1